Joining FORCES is the FORCE newsletter with news, views and supportive information for individuals concerned about hereditary breast and ovarian cancer.
Men and women aged 18 years or older who have advanced (metastatic) breast cancer due to a BRCA1 or BRCA2 gene mutation may qualify for the Brocade Study. The purpose of this medical research study is to determine the safety and effectiveness of the investigational PARP inhibitor, Veliparib in combination with chemotherapy in patients with advanced hereditary breast cancer. Each individual will be evaluated to determine his or her eligibility. Those who qualify will receive investigational medication or placebo, study-related medical exams, and lab tests at no charge. Compensation for time and travel may also be available. To see if you may qualify, call 1.855.5ONCOLOGY (1.855.566.2656) or visit BrocadeStudy.com.